Skip to main content
. 2022 Aug 29;89:106152. doi: 10.1016/j.ultsonch.2022.106152

Fig. 11.

Fig. 11

Antiproliferative activity of EGY-PAM and YEM-PAM against two cancer cell lines: hepatocellular carcinoma (Hep-G2) (A); and breast cancer cell lines (MCF7) (B).